Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

Avalo Therapeutics, Inc.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Biotechnology Value Fund L.P. amended its Schedule 13G stake filing for Avalo Therapeutics, Inc., disclosing the change to the SEC under accession number 0000921895-26-003170. The filing updates the fund's previously reported ownership position in the clinical-stage biotech. The amendment signals a shift in the institutional holder's stake, though the filing did not specify the size of the change. Investors will watch for further 13G or 13D filings to gauge whether the fund is accumulating or trimming its position.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Avalo Therapeutics, Inc., BIOTECHNOLOGY VALUE FUND L P